Clinical Trials Logo

Clinical Trial Summary

This is a Phase IV, multicenter, open-label study of Asceniv™ administered as an intravenous infusion of Asceniv™ (IGIV) 300-800 mg/kg every 21 or 28 days in approximately 12 pediatric subjects with Primary Immunodeficiency Diseases (PIDD). The study will be conducted at 5-7 centers in the United States, with subjects receiving six (28 day cycle) or seven (21 day cycle) doses of Asceniv™ during the study.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05070455
Study type Interventional
Source ADMA Biologics, Inc.
Contact Rebecca Avila
Phone 561-989-5853
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date October 1, 2021
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT01199705 - Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) Phase 3
Recruiting NCT03836690 - Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation Phase 1
Completed NCT01461018 - Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study) Phase 3
Recruiting NCT04581460 - Primitive Immunodeficiency and Pregnancy
Completed NCT00419341 - Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy Phase 3
Active, not recruiting NCT02868333 - Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagnosed During Childhood N/A
Completed NCT01166074 - Retrospective Chart Review of Subcutaneous IgG Use in Infants N/A
Recruiting NCT04784364 - Biologics And Clinical Immunology Cohort at Sinai
Recruiting NCT04459689 - COVID-19 in PID Survey
Completed NCT02711228 - Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Phase 4
Recruiting NCT04919018 - Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies
Completed NCT00719680 - Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) Phase 3
Terminated NCT00023504 - Antibody Production in Immune Disorders Phase 4
Recruiting NCT00246857 - Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Recruiting NCT04565015 - Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency Phase 3
Recruiting NCT04702243 - Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults
Recruiting NCT04640142 - Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases Phase 3
Completed NCT00680446 - Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency Phase 3